Chemical combination effects predict connectivity in biological systems

Joseph LeHá´r1,2,*, Grant R Zimmermann1, Andrew S Krueger2, Raymond A Molnar1, Jebediah T Ledell1, Adrian M Heilbut1, Glenn F Short III1, Leanne C Giusti1, Garry P Nolan1, Omar A Magid1, Margaret S Lee1, Alexis A Boris1, Brent R Stockwell3 and Curtis T Keith1

1 CombinatoRx, Incorporated, Cambridge, MA, USA, 2 Bioinformatics and Biomedical Engineering, Boston University, Boston, MA, USA and 3 Department of Chemical Sciences and Department of Chemistry, Fairchild Center, Columbia University, New York, NY, USA

* Corresponding author. CombinatoRx, Incorporated, 245 First St, Cambridge, MA 02142, USA. Tel.: +1 617 301 7151; Fax: +1 617 301 7110; E-mail: jlehar@combinatorx.com or jlehar@alum.mit.edu

Received 13.7.06; accepted 23.11.06

Efforts to construct therapeutically useful models of biological systems require large and diverse sets of data on functional connections between their components. Here we show that cellular responses to combinations of chemicals reveal how their biological targets are connected. Simulations of pathways with pairs of inhibitors at varying doses predict distinct response surface shapes that are reproduced in a yeast experiment, with further support from a larger screen using human tumour cells. The response morphology yields detailed connectivity constraints between nearby targets, and synergy profiles across many combinations show relatedness between targets in the whole network. Constraints from chemical combinations complement genetic studies, because they probe different cellular components and can be applied to disease models that are not amenable to mutagenesis. Chemical probes also offer increased flexibility, as they can be continuously dosed, temporally controlled, and readily combined. After extending this initial study to cover a wider range of combination effects and pathway topologies, chemical combinations may be used to refine network models or to identify novel targets. This response surface methodology may even apply to non-biological systems where responses to targeted perturbations can be measured.

Molecular Systems Biology 27 February 2007; doi:10.1038/msb4100116

Subject Categories: metabolic and regulatory networks; simulation and data analysis

Keywords: chemical genetics; combinations and synergy; metabolic and regulatory networks; simulation and data analysis

Introduction

Living organisms are built of interacting components, whose function and dysfunction can be described through dynamic network models (Davidson et al., 2002). Systems Biology involves the iterative construction of such models (Ideker et al., 2001), and may eventually improve the understanding of diseases using in silico simulations. Such simulations may eventually permit drugs to be prioritized for clinical trials, reducing potential risks and increasing the likelihood of successful outcomes.

Owing to the staggering complexity of biological systems, efforts to model them require large and diverse sets of data on connections between components and responses to system perturbations. Among the most advanced models are those developed for baker's yeast, Saccharomyces cerevisiae (Zhang et al., 2005), which are built upon protein–DNA (Lee et al., 2002) and protein–protein (Ho et al., 2002) associations, supplemented by correlated changes in gene expression (Hughes et al., 2000) or protein abundances (Gygi et al., 1999) under differing conditions. Information gleaned from targeted synergies, such as paired mutations (Tong et al., 2004) and gene–drug interactions (Parsons et al., 2004), have proven to be especially useful for revealing functional connections between components. Chemical combinations also show promise, and a proliferation experiment with yeast mutants in the presence of probe mixtures (Haggarty et al., 2003) has found that chemical profiles correlate with genetic similarity. This potential is confirmed by recent experiments using antibacterial combinations (Yeh et al., 2006) that show a relationship between synergy and chemical target relatedness.

Combination responses to varying concentrations of compounds provide a more detailed look at synergistic perturbations. Combination therapies have been used increasingly over the past century, and comprehensive reviews (Berenbaum, 1989; Greco et al., 1995) describe the experimental designs and combination analyses employed. Combinations of two or more agents can be tested using either exhaustive or efficient designs (Carter and Wampler, 1986), and the most widely used is the factorial design (also ‘checkerboard’ or ‘dose matrix’) where combinations are tested in all possible permutations of serially diluted single agent doses (Figure 1). A dose-matrix experiment comprehensively samples the underlying response surface with few assumptions about its shape. We have previously reported an approach for high-throughput dose-
matrix screening of chemical combinations (Borisy et al., 2003; Keith et al., 2005; Zimmermann et al., 2007) in cell-based assays that preserve disease-relevant biological connections. Such screens yield a variety of response surfaces, with distinct shapes for combinations that work through different known mechanisms, suggesting that combination effects may contain information on the nature of functional connections between drug targets.

The past study of drug combinations has focused mainly on the question of whether a combination is more potent than equally effective doses of its constituents (Greco et al., 1995).

Synergy over this level is especially important when justifying clinical uses, as it defines the point at which the combination can provide additional benefit over simply increasing the dose of either agent. This most widely used dose additivity model (Loewe, 1928) represents the expected response if both agents are actually the same compound. In that case, a slice through the response surface at any chosen iso-effect level (or ‘isobole’) should show a linear relationship between the doses of the two agents. For example, if 50% inhibition \((I=\frac{T}{U})\) for treated and untreated samples) is achieved separately by 1 \(\mu M\) of drug A or 2 \(\mu M\) of drug B, a combination of 0.5 \(\mu M\) of A and

---

**Figure 1** The morphology of cell-based dose-matrix responses to chemical combinations differs between mechanisms. Data for two synergistic antibacterial combinations using a methicillin-resistant *Staphylococcus aureus* strain are shown in three-dimensional projections. In Augmentin\textsuperscript{®} (A), clavulanate disables a bacterial defence against penicillin drugs, whereas both agents in Bactrim\textsuperscript{®} (B) inhibit enzymes in folate metabolism. The mechanisms of action differ between the two combinations, as do the shapes of their response surfaces. Dose-matrix response surfaces show the inhibition of growth \((I=\frac{T}{U})\) for each pairwise permutation of the serially diluted single agent doses. The 2D maps (C, D) show a top-down view of the surface, using the same colours for inhibition levels, to better display mathematical descriptions of the shape without obscuring any data, and permit many matrices to be shown together with clarity.
1 μM of B should also inhibit by 50%. Formally, the response at combined concentrations \( X \times Y \) is the inhibition \( I_{\text{Loewe}} \) that satisfies \( (X/X_1) + (Y/Y_1) = 1 \), where \( X_1 \) and \( Y_1 \) are the single agent effective concentrations that produce \( I_{\text{Loewe}} \). Deviations from Loewe additivity are usually quantified using the combination index (Chou and Talalay, 1983) \( CI = (X/X_1) + (Y/Y_1) \), which is essentially a ratio of total effective drug dose (combination versus single agents) required to achieve a given effect level. Loewe additivity is experimentally demanding because determining the effective concentrations requires well-sampled single agent curves. Moreover, the dose-additive constraint is not in closed form; so Loewe additive response surfaces generally must be computed using iterative root finding (Berenbaum, 1985). The other frequently used reference model is Bliss independence (Bliss, 1939), which is the expectation (multiplicative probabilities) for independent yet competing elimination agents, like bullets aimed at a limited set of targets. For inhibitions, \( I_{\text{Bliss}} = I_X + I_Y - I_X I_Y \), where \( I_X \) and \( I_Y \) are the single agent inhibition levels at concentrations \( X \) and \( Y \). Although this model is of questionable relevance to drugs in biological settings, Bliss independence has often been favoured because it can be directly calculated from minimally sampled experiments without single agent response curve interpolation or iterative root finding. A third useful reference is the highest single agent (HSA) model, or Gaddum’s non-interaction (Berenbaum, 1989), where the expected combination effect is simply the maximum of the single agent responses at corresponding concentrations.

The relationship between combination effects and drug mechanism has been intuitively recognized for some time, but attempts to theoretically model this association (Ashford and Cobby, 1974; Harrap and Jackson, 1975; Jackson, 1993) have proven problematic. These studies simulated a branched metabolic pathway as a system of linked ordinary differential equations, and the final reaction velocity was calculated in response to varying concentrations of inhibitors targeting different modelled enzymes. Synergy over Loewe additivity was assessed for each pair of enzyme inhibitors by computing simulated dose matrices and reporting the smallest combination index at 50% inhibition. However, these efforts could not unambiguously predict synergy or antagonism, because it was possible to generate any combination index for most inhibitor pairs by varying one or more of the many kinetic parameters in the pathway model.

We approached the problem by focusing not just on the presence or absence of synergy relative to some reference level, but by using a set of shape models to characterize the morphology of full response surfaces. Here we show that there is a clear relationship between dose-matrix response shape for a combination and the connectivity of its targets (the type of connection between them), using simulated pathways and combination experiments. The simulations were used to define a reference set of shape models that represent connectivity-related responses, and the experiments demonstrated that the shapes predicted by the simulations do indeed occur in biological settings. We also use the data to show that the synergy profile produced by a drug across many combinations in a screen depends on the drug’s mechanism, and can also be used to infer connectivity relationships between drug targets.

**Results**

We considered four models for combination effect morphology (Figure 2 and Materials and methods) that reflect historical combination analyses and that represent many of the responses observed in our therapeutic combination screens. The HSA model describes a simple superposition of the single agent curves. Loewe additivity (Loewe, 1928) is the drug-with-itself reference to represent dose-additive pairings. The ‘Bliss boosting’ model extends Bliss Independence (Bliss, 1939) to allow variable boosts in effect at high concentrations. Finally, the ‘Potentiation’ model describes combinations like Bactrim® (Figure 1), where one agent’s curve is shifted with a power-law slope and superposed on the enhancer’s own activity. These models are not an optimally designed basis set of shape descriptors because they are not orthogonal (they produce
degenerate, or indistinguishable, shapes for some parameter settings), and also are not complete, in that some observed surfaces do not fit any of them. Nevertheless, this set does cover many of the observed effects in our therapeutic screens, and permits a quantitative exploration of different synergy types. Each observed dose matrix can be analysed by fitting all the shape models to the data by means of least-squares minimization across any free parameters, and determining which shape models produce consistent fits. It is also useful to calculate a volume \( V_{HSA} \) between the data and the HSA surface, normalized to the concentration sampling, to characterize the overall strength of combination effects.

### Simulations of metabolic pathways

We used numerical simulations of metabolic pathways to show that pairs of targets with differing connectivity produce distinct combination effects (Figure 3). We constructed a branched, unregulated pathway of linked Michaelis–Menten reactions (Supplementary 1), and computed the inhibition of final reaction velocity after applying varying concentrations of paired competitive enzymatic inhibitors (affecting \( K_m \)). Each pair of inhibitors was applied repeatedly over a dosing matrix, and we determined the response morphology by fitting our shape models to each simulated dose matrix, and finding which shape provided the best match over the whole surface (Figure 3). We found that when both inhibitors targeted the same enzyme, Loewe additive surfaces were produced as expected. When the inhibitors had separate targets within this pathway, the resulting surfaces were best fit by Bliss boosting, with differing levels depending on the target connectivity.

These differences in combination effect were robust to plausible variations of the simulated pathway that did not affect the network topology. Random perturbations of up to two orders of magnitude in all the reaction parameters recovered the original best-fit shapes (Supplementary Figure S2), suggesting that the response morphology is affected by only such extreme changes in kinetic parameters that alter the network topology. Similar Monte Carlo simulations perturbing specific parameter classes or individual enzymes showed no strong sensitivities to particular kinetic parameters or targets for this pathway (Supplementary 3). Converting the inhibitors to non-competitive (affecting \( V_m \)) kinetics likewise recovered the original best-fit shapes, altering mainly the single agent curves. An exception is that unbypassed serial combinations (e.g., R1xR6; Figure 3) yielded HSA-like responses for non-competitive inhibitors (Supplementary 2). Adjusting the end point to something more like proliferation by means of an exponential transform (see Materials and methods) distorted the resulting boost levels, but still did not change which shape model was preferred. All of these factors could strongly affect the single agent curves (e.g., potency, steepness, and limiting efficacy) but the best-fit shape model for each simulated combination effect was very stable to perturbation.

Introducing regulation by negative feedback did have strong effects on the combination responses. Pathway B was added to investigate synergy across pathways and to predict effects for sterol biosynthesis. Whereas inhibitors with serially placed targets in an unregulated linear pathway produced multiplicative boosts, enclosing such targets in a negative feedback loop yielded strong potentiation (although like unregulated serial inhibitors, these yield weaker effects for non-competitive inhibitors). The synergies under negative feedback are not immediately intuitive (Supplementary Figure S3) and an analytical derivation of the simulated power-law potentiation for this model would be challenging, underscoring that simulation is the most practical means for deriving even the simplest emergent properties of complex systems.

Another change affecting topology is to alter the type of junctions in a pathway. For the branches in Pathway A, the reaction could proceed down either side to the end point; so parallel pairs of inhibitors across these junctions (e.g., R3 with R5) are functionally analogous to logical OR operations. Inhibiting across such OR junctions produced saturating Bliss responses in our simulations. Replacing such junctions with functional AND operations (here implemented by pairing targets across Pathway A and Pathway B, both required for \( R_{AB} \) ) resulted in masking surfaces (close to HSA or Bliss masking) for combinations that straddled the junction. Such masking effects were produced even for cross-pathway combinations involving R11 and R12, which are bypassed in Pathway B to ensure clear distinctions between masking, multiplicative, and saturating boosts.

The best-fit shapes for all the combinations in both simulated pathways are summarized in Figure 4, using symbols whose size reflects the HSA volume and where the colour and symbol denote the best-fit model. The ambiguity between the shape models for each combination is illustrated in Supplementary Figure S4. In these simulations, the fitted shapes clearly correspond to distinct mechanistic configurations. It is notable that all the cross-pathway combinations produced either HSA surfaces or other masking surfaces with weaker combination effects (with \( |V_{HSA}| \sim 1 \), between the measured effect and the HSA model surface) than are seen within each of the pathways (\( |V_{HSA}| \sim 3–10 \)).

These simulations suggest specific hypotheses in terms of our shape models for experimental combinations of chemical inhibitors of metabolic pathways. Agents sharing a primary target should, of course, produce Loewe additive responses. Branched unregulated pathways should produce various levels of Bliss boosting, depending on the target connectivity, and linear pathways regulated by negative feedback should show power-law potentiation. Combinations with targets that cross between such pathways are likely to produce masking effects (similar to the HSA model or Bliss masking).

### Yeast combinations experiment

To test some of the hypotheses from our simulations, we undertook a chemical combination screen focused on the sterol metabolism in yeast. This pathway is very well characterized with known inhibitors at a number of enzymes (Wills et al., 2000), and is regulated by negative feedback (Gardner et al., 2001). We selected 10 antifungal drugs (Table I), six with targets along a linear section of the pathway and four targeting other cellular functions. Because sterol biosynthesis is much the same across yeast species (Wills et al., 2000), we selected *Candida glabrata*, a frequent focus of antifungal treatment that we had used in past therapeutic screens, and measured proliferation using a metabolic assay (Materials and
methods). After determining single agent activities for all the drugs, we designed dose-matrix experiments with concentration samples centred on each drug’s effective concentration at 50% effect (EC₅₀) when possible.

The dose-matrix responses for each combination are presented in Figure 5 and Supplementary 4. The combination effects are visible towards the top right-hand corner of each response surface, especially between the sterol pathway inhibitors. Some of the single agents produced variable responses, and this is most obvious for those drug-with-itself dose matrices along the diagonal of the grid which show only one side appearing to be active. The self-combination of
rapamycin illustrates how a spurious synergy can arise from instability in the measured potency of a drug, and the apparent synergy of miconazole and itraconazole shows evidence of single agent instability—its inhibition errors are exceptionally large, indicating inconsistency between the replicate blocks.

Figure 4 The best-fit shape models for our simulated pathway (Figure 3) consistently depend on target connectivity. Combination effects between competitive inhibitors are shown as symbols whose area is proportional to the HSA volume and whose colour indicates the best-fit model shape; black for HSA, blue for Loewe additivity, green for Bliss boosting, red for potentiation, and grey when two or more models could not be distinguished (see Supplementary Figure S4). The Bliss boosting model is subdivided using shape to indicate the boosting level (square for saturating, diamond for multiplicative, circle for masking, and open circle for suppressing). The bold lines separate Pathway A from Pathway B combinations, and the thin lines partition Pathway A into its component sections. All inhibitor-with-self pairings fit Loewe additivity, as expected. Other combinations within Pathway A consistently fit the Bliss model with distinct boosting levels. Cross-target combinations within the negative feedback in Pathway B consistently show potentiation, and cross-pathway combinations always have masking responses (close to Bliss masking, additivity, or HSA).

Much more striking are the synergies between sterol inhibitors, which span a greater range of concentrations and which recapitulate the known antifungal synergy between statins and azoles (Lorenz and Parks, 1990).

The shape and magnitude of each combination effect is summarized by symbols whose size represents the total synergy (as measured by $V_{\text{HSA}}$) and whose colour denotes the best-fit shape model. Degeneracies between the models are measured by the comparative chi-squared ($\chi^2$) goodness-of-fit estimates (Supplementary 4 and Supplementary Figure S5). Although the data quality did not permit a clear distinction between the HSA model and Loewe additivity, the two most similar models in the set, most of the drug pairs sharing the same targets and agent-with-self combinations produced responses that were consistent with Loewe additivity. The exceptions all had relatively weak synergy, with only one, itraconazole with Miconazole, exceeding the estimated systematic error level ($V_{\text{HSA}} > 1$; see Materials and methods). By contrast, all but one of the cross-target sterol combinations exceeded that level, and all produced surfaces that were best fit by potentiation. Across pathways, the combination effects were more variable, and strong synergies ($V_{\text{HSA}} > 1$; see Materials and methods) were relatively rare (5/28 versus 10/22 for same pathway), with an $\sim 8\%$ Poisson probability (Press et al, 1997, §14.3.3).

The observed effects confirm predictions from our pathway simulations. We expected same-target combinations to produce Loewe additivity and cross-target sterol pairings to give rise to potentiation. Among the 11 same-target and 11 cross-target sterol combinations tested, the prediction accuracy is only 54% if we insist on unambiguously correct shape classifications (the predicted model has $\chi^2_{\text{min}}$, and $\Delta \chi^2 > \chi^2_{\text{min}}$ for the next best fit). However, almost all the failures are due to the degeneracy of the models for HSA-like combinations. If we count as a success any surface whose best fit was indistinguishable from the predicted shape, with $\Delta \chi^2 < \chi^2_{\text{min}}$, the prediction accuracy rises to 72% with an uncertainty of $\sim 22\%$ due to the sample size, assuming Poisson statistics within each confusion matrix class. Across pathways, the relative diversity of combination effects makes sense, because their target connectivities are probably more varied, and the relative rarity of strong synergies accords with the

### Table 1 Drugs used in the C. glabrata proliferation experiment

| Drug name          | Abbrev. | CAS number     | Conc. range (µM) | Target function  | Target gene/protein |
|--------------------|---------|----------------|------------------|------------------|---------------------|
| Cerivastatin       | CERV    | 145599-86-6    | 0.47–7.6         | Sterol synthesis | HMG1, HMG2         |
| Alerdonate         | ALND    | 121268-17-5    | 3.0–48           | Sterol synthesis | ERG1                |
| Terbinafine        | TERB    | 78628-80-5     | 1.9–30           | Sterol synthesis | ERG1                |
| Fluconazole        | FLUZ    | 86386-73-4     | 2.0–32           | Sterol synthesis | ERG11               |
| Itraconazole       | ITRZ    | 84625-61-6     | 0.06–1.0         | Sterol synthesis | ERG11               |
| Miconazole         | MICZ    | 75319-48-1     | 0.03–0.21        | Sterol synthesis | ERG11               |
| Kapamycin          | RAPM    | 53123-88-9     | 6.2–100          | Cell signalling  | TOR1, TOR2         |
| Pentamidine        | PENT    | 140-64-7       | 0.53–8.5         | Various           | CDH1, SDH1, MRP3    |
| Amphotericin B     | AMPT    | 1397-89-3      | 0.09–1.4         | Cell wall         | ACC1, FKS1          |
| Caspofungin        | CASP    | 162808-62-0    | 0.06–1.0         | Cell wall         | FKS1                |

*aRine et al (1983).  
*bBergstrom et al (2000).  
*cLum et al (2004).  
*dGaeve et al (2004).  
*eTerrell and Hughes (1992).  
*fDouglas et al (1997).
predominantly masking effects in our simulated cross-pathway combinations.

Combination screen in human tumour cells

There is further support for our simulations from a prior combination screen aimed at discovering potential combination therapeutics. Human tumour cells (HCT116) were tested using a proliferation assay for responses to all pairwise combinations of 90 drugs and probes, most with known mechanism (Supplementary 5). This screen provides a broader sampling of possible target connectivities than had our C. glabrata experiment, and permits us to investigate the applicability of our shape models to cellular signalling networks. Because this screen had been designed for discovering potent synergies, a four-fold dilution factor had been used (compared to two-fold for our yeast experiment), and many compounds were either inactive alone or had not been sampled far above their EC50 concentrations, often obscuring distinctions between fitted shape models. Nevertheless, we expect strong potency shifts to be nearly always detectable, and other shape classes can be distinguished when the single agents have been appropriately sampled.

For each combination, we obtained an HSA volume \( V_{\text{HSA}} \) and best-fit shapes as described above. We also examined ‘synergy profiles’ constructed from each agent’s \( V_{\text{HSA}} \) values across all the other probes, and recorded the correlation coefficient between the synergy profiles for each pair of drugs in the screen. Each pair of drugs was classified by target relatedness, using the known target annotations (Supplementary 5), as ‘Identical’ for drug-with-itself, ‘Same’ for drugs sharing a target, ‘Related’ for pairs with distinct targets in the same pathway or function, ‘Different’ for pairs targeting distinct functions, and ‘Unknown’ for pairs involving at least one uncharacterized drug. Inter-kinase combinations were classified separately as ‘Kinesases’. Supplementary 6 presents the resulting scores and correlations for all the tested combinations, and Supplementary 7 shows their distributions grouped by target similarity.

The shape models in Figure 2 provide reasonable coverage of the observed combination effects. Only \( \chi^2 \text{min} < 2 \) of 4092 drug pairs in the screen produced a formally acceptable fit (\( \chi^2 \text{min} < 2 \)) to any of the models (Supplementary 7a). However, given the systematic errors produced by the experimental process (Materials and methods), a more fair assessment of the uncertainties can be obtained by examining the \( \chi^2 \) distribution of the Loewe additive model for the 87 drug-with-self combinations, as a negative control set. These ‘Identical’ combinations have a median additive \( \chi^2 \text{med} \approx 9 \), suggesting that the uncertainties are roughly three times larger than the formal estimates from replicate dose matrices, due to systematic errors that were not accounted for by the scatter between replicates. Adopting this \( \chi^2 \) level as more representative of the errors extends the coverage (\( \chi^2 \text{min} < 18 \)) of our models to most of the

Figure 5 Validation of expected combination effects in a yeast experiment focused on sterol biosynthesis. In yeast, the sterol pathway (left) produces ergosterol, an essential cell wall component, through a series of metabolic enzymes (grey symbols) acting on intermediate substrates (black symbols), and regulated by negative feedback (dotted connections). The experiment tested C. glabrata proliferation responses to all combinations of 10 antifungal drugs (Table I), six with known targets on the sterol pathway (inhibitor markers). The results are shown (centre) with concentrations increasing from the bottom left of each drug pair’s dose matrix. The combination effect symbols (right) summarize the observed response for each pair in terms of the models presented in Figure 2. Size shows synergy as measured by \( V_{\text{HSA}} \), the volume between the data and HSA surface. The best-fit shape model is indicated by colour: black for HSA, blue for Loewe additivity, green for Bliss boosting, red for potentiation, and grey when two or more models could not be distinguished (see Supplementary Figure S5). Drug pairs sharing a target mostly produced weak responses (\( V_{\text{HSA}} < 1 \)) consistent with Loewe additivity, and cross-target sterol combinations produced potentiation, as expected for a linear pathway under negative feedback (\( \approx 70\% \) prediction accuracy). Combinations involving non-sterol drugs showed fewer strong combination effects and their synergy profiles across all the drugs were more variable.
screen, leaving only ~10%, which are dominated by those combinations that are equally inconsistent with all four models.

For an analysis of the observed shape distributions, we selected a set of ‘optimally sampled’ combinations, where at least two concentration samples had been tested above the EC_{50} for both single agents, enabling distinctions between strong combination effect shapes. Among these 253 combinations, ~60% fit masking models (HSA, additive, or Bliss masking), ~30% were best fit by potentiation, with the remaining ~10% accounted for by multiplicative or saturating Bliss boosts. These proportions hold even for the 91 optimal combinations with sub-saturated single agent activities (E_{\text{max}} < 90%), for which masking and multiplicative effects would be clearly distinguishable. For all target connectivity groupings, the optimally sampled combinations were dominated by masking and potentiation effects.

Across the whole screen, combination effects and synergy profile correlations (Figure 6A and B) support the trends observed in our pathway simulations and the C. glabrata experiment. When we examined synergy score distributions (Supplementary 7), we found that drug pairs targeting different pathways or involving unknown targets had significantly more variable scores (Materials and methods) with a slight trend to lower synergy levels. The synergy profile correlations show a more striking trend. Pairs with the same or related targets ought to have similar connectivities with the rest of the set, because they are likely to have similar mechanistic relationships to the rest of the drug targets in the screen. Indeed there are significant differences between the profile correlation distributions with a stronger trend towards increasing correlation with target similarity.

The responses to pairings of kinase inhibitors also provide support for an association between combination effects and connectivity. Whereas combinations between kinases in general had similar distributions to those for other related target pairs, combinations between drugs targeting the phosphatidylinositol-3 kinase (PI3K), protein kinase C (PKC), or mitogen-activated protein kinase (MAPK) signalling pathways (Table II) showed exceptionally strong synergies and correlations. HCT116 cells maintain an activating KRAS mutation that drives cellular growth and survival (Shirasawa et al., 1993), and are especially reliant upon epidermal growth factor receptor (EGFR)-mediated signalling for proliferation (Awwad et al., 2003). Because these pathways are central to EGFR signalling and interconnected (Schlessinger, 2004), we would expect HCT116 cells to be very sensitive to these combinations, and that inhibitors of those pathways should have similar synergy profiles. Moreover, the combination effects between the pathways show differences (Figure 6C) that are consistent across mechanistic replicates, despite limited concentration sampling and evidence of secondary target activity. Such differences may eventually provide novel insights into how these pathways interact in the context of HCT116 proliferation (e.g., that the MAPK/PKC connection may be less direct than the other target pairings).

Discussion
The simulations and experiments presented here add a new dimension to earlier studies investigating the effects of multiple perturbations to biological systems. Early studies of statistical epistatic associations between random mutagenesis
Chemical combinations and target connectivity

J Lehar et al

Table II Drugs targeting EGFR signalling used in the HCT116 proliferation experiment

| Drug name   | Abbrev. | CAS number | Conc. Range (µM) | Target kinase |
|-------------|---------|------------|------------------|---------------|
| U-0126      | U0126   | 109511-58-2| 0.10–26          | MAPK/MEK<sup>9</sup> |
| 5-iodotubercidin | TUBC     | 24386-93-4 | 0.04–10          | MAPK/ERK<sup>6</sup> |
| LY 294002   | LY294   | 154447-36-6| 0.13–33          | PI3-K<sup>6</sup> |
| Wortmannin  | WORT    | 19554-26-7 | 0.09–23          | PI3-K<sup>6</sup> |
| GF 109203X  | GFI09   | 133052-90-1| 0.08–21          | PKC<sup>6</sup> |
| Ro 31-8220  | RO-31   | 138489-18-6| 0.04–9.8         | PKC<sup>6</sup> |
| Rottlerin   | ROTT    | 82-08-6    | 0.08–19          | PKC<sup>6</sup> |

<sup>9</sup>Favata et al (1998).
<sup>6</sup>Pox et al (1998).
<sup>6</sup>Yano et al (1995).
<sup>6</sup>Oka et al (1994).
<sup>6</sup>Toule.com et al (1991).
<sup>6</sup>Davis et al (1992).
<sup>6</sup>Gschwendt et al (1994).

and chemical stresses (Elena and Lenski, 1997; Kishony and Lebler 2003) were followed by systematic studies of mutant libraries in combination with chemical probes (Giaever et al, 2004; Lum et al, 2004; Parsons et al, 2004) and synergies between targeted chemical probes (Haggerty et al, 2003; Yeh et al, 2006). This study explores the additional information available from variable dose response matrices, and relates quantitative combination effects, as measured response shape classification or by HSA volumes, to target connectivity. We use the term ‘connectivity’ to capture both the distance and topology of the connection between the targets, rather than the more common ‘interaction’ (Parsons et al, 2004), denoting the presence of a functional connection. Our pathway simulations show that biological systems are expected to produce a useful variety of combination effects that are correlated with connectivity, and our experimental results demonstrate that the simulations are biologically relevant and predictive.

There was only partial consistency between specific chemical synergies in our yeast experiment and corresponding interactions observed in earlier genetic screens (Supplementary 8). The observed synergies between sterol inhibitors are reflected in homozygous synthetic lethalities (Stark et al, 2001) that are internal to the pathway, and rapamycin’s synergy with terbinaine agrees with the reported interaction between TOR1 and ERG1. However, the mutant screen of caspofungin’s target, FKS1, showed no correlation with our combination effects. Moreover, there is little correspondence between our results and the cross-activities identified in drug sensitivity screens of heterozygous yeast mutants (Giaever et al, 2004; Lum et al, 2004; Parsons et al, 2004). The mixed results of these comparisons are not very surprising. Aside from experimental errors (see Materials and methods), some of the disagreement can be ascribed to the quantitative nature of dose-matrix response data, because the responses to varying doses (Hartman and Tippery, 2004), or even time-resolved experiments (Warringer et al, 2003), can detect the effects of non-essential genes that would have been missed in lethality screens. Another contribution may come from likely differences between genetic and protein networks (Ozier et al, 2003). Chemical combinations can interfere directly with protein interactions without mediation through gene expression, and although the protein and gene networks are intertwined, connectivity differences between the two types of targets should be expected.

There was more agreement between our simulation results and a prior flux balance analysis (FBA) of the yeast metabolic network (Segre et al, 2005) in response to paired mutations. The simulated mutations should correspond roughly to the high-concentration limit of our dose matrices. Both approaches predict strong synergies (synthetic lethality) when the system is inhibited across parallel alternative pathways, and find masking effects (buffering) when unrelated pathways are impaired, provided that the two pathways are not competing for a common supply of precursors (Supplementary Figure S2 in Segre et al). The main difference is that the FBA simulations produced more multiplicative than masking pairings, especially for cross-pathway combinations. This may be due to the partial view of combination effects provided by the epistasis scores (Supplementary Figure S1), or to an implicit assumption, in the FBA simulations, that competition for the same metabolic ingredients is widespread. The masking responses found in our cross-pathway simulations are supported experimentally, by the weaker synergy levels seen in our C. glabrata experiment, and by the large fraction of masking effects (~60%) in both the HCT116 screen and prior antibacterial combination experiments (Yeh et al, 2006).

Thus the dose-matrix response shapes and synergy profiles from systematic combination screens can provide valuable new insights into network connectivity. A possible application in chemical genetics would be to extend phenotypic profiling for mechanism inference (Perlman et al, 2004; Macdonald et al, 2006), using combinations effectively as extra assays. Query drugs with unknown targets could have their synergy profiles compared to a previously assembled profile library for a diverse set of chemical probes. The known targets for those probes whose profiles correlate most closely with a query drug’s are likely candidates for the drug’s mechanism. For constructing biological network models, observed combination effects can be compared to expectations from target connectivity through existing protein interaction networks, and inconsistencies can be used to improve the models by means of a prediction-validation procedure (Ideker et al, 2001). Combining chemicals is much simpler than the process of constructing double mutant strains, and chemical combinations can yield detailed information about connections between proteins that are not accessible to single agents or mutagenesis, enabling the study of disease networks like those involved in cancer (Schoeberl et al, 2002) and inflammation (Bouwmeester et al, 2004) signalling.

Of course, there are limitations to this approach for probing biological networks. The collection of full dose matrices is expensive, and will necessitate a trade-off between the added information obtained from response shapes and the loss of assay fidelity from the use of high-throughput measurements (e.g., single time points for growth rather than time-resolved growth curves). The mechanistic information that can be extracted will depend strongly on the generality and specificity of the set of shape models being used. The four models presented here represent only a subset of the observed responses, and the pathway simulations sampled only a small minority of possible target connectivities. Even with more...
extensive simulations, there will certainly be mechanistic
degeneracies associated with each distinct response shape. For
example, it will probably be possible to produce potentiation
like that seen in Bactrim using several distinct target
configurations. Thus, response shapes cannot be used to
uniquely define combination mechanisms, but merely to
exclude inconsistent connections. Finally, chemical probes
often have poorly characterized mechanisms or multiple
targets, and combination screens will have to account for this
by covering biological targets with several chemically distinct
probes. Despite all these limitations, the present study has
shown that even with a limited set of shape models, dose-
matrix data can provide useful connectivity information.

The results of this initial exploration suggest several
directions for expanding the response surface approach to
combination analysis. First, it is essential to extend the current
shape model set by using more comprehensive simulations of
larger networks. The most obvious way to do this would be to
define a basis set that represents simple observed network
connectivities, including serial and parallel arrangements,
bifurcations, both AND and OR junctions, and some regulation
mechanisms (Milo et al, 2002). Combination responses from
pathway simulations covering the connectivity basis could
then be used to define shape models for comparison with
simulated responses for larger networks, as well as with
experimental data. Another approach would be to system-
atically explore perturbations of an existing biological net-
work, such as S. cerevisiae metabolism (Famili et al, 2003),
and to model drug inhibition by partially restricting the reaction
rates at metabolic enzymes, essentially the Segré et al’s FBA
for partial inhibitors. The challenge with this approach would
be to identify meaningful connectivity measures that correlate
with simulated synergy types. A third very promising area for
future exploration is higher order combinations. The emer-
gence of resistance to treatment for afflictions like cancer (Fojo
and Bates, 2003) can be effectively addressed by combinations
of three or more drugs (Komarova and Wodarz, 2005).
Combination approaches can also offer improved control by
perturbing multiple components of the disease network
(Csermely et al, 2004), and higher order combinations should
provide yet more details on mechanistic connections between
their targets. The response surface approach presented here
can be readily adapted to three or more drugs, as can the
specific shape models shown in Figure 2, and a metabolic FBA
of higher order combinations should provide important
insights into the effectiveness of multi-target treatments.
Finally, because the simulated combination responses were
insensitive to the reaction details, this methodology may even
be extendable to non-biological network problems where
responses to targeted perturbations can be measured (Milo
et al, 2002).

Materials and methods
Combination response shape models
Experimental dose-matrix responses include both potency shifts,
where a combination alters the apparent potency of the single agents,
and efficacy boosts, where the joint effect exceeds levels possible for
either of the constituents. Many of these responses can be described by
simple models that use the single agent curves to predict the
combination effect (Figure 2), and whose parameters provide quantitative measures. Strong potency shifts relative to a simple HSA
surface can be described using a power-law potentiation model, and
efficacy boosts are quantifiable using a model that extends Bliss
Independence (Bliss, 1939) to variable combination effect levels at
high concentration. These models are expressed in terms of inhibi-
tions, but can be adapted to other types of measurement, or for
combinations involving more than two perturbing agents, without
altering their qualitative properties. The shapes presented are not a
complete orthogonal set covering all expected combination responses,
but were chosen to represent some of the variety seen in our
therapeutic screens, as well as to reflect historical reference models
used in the literature.

The HSA model, or Gaddum’s non-interaction (Berenbaum, 1989),
is based simply on the intuition that if a combination’s effect exceeds
those of its constituents, there must be some interaction. Mathema-
tically, the HSA model is a superposition of the single agent curves
where, at any combined concentration (X,Y), the inhibition
\[ I_{HSA} = \max\left(I_X, I_Y\right) \]
where \( I_X \) and \( I_Y \) are effects produced by the single
agents at (0,0) and (0,Y). The model values are calculated at each dose-
matrix point, where \( I_X \) and \( I_Y \) were determined using sigmoidal fits to
the single agent response data. The volume \( V_{HSA} = \frac{1}{2} x \ln f_{I_{HSA}} \) between the data and the HSA surface, adjusted for variable dilution factors \( f_X, f_Y \) can be readily calculated and provides a practical
overall measure of synergy (in units of inhibition), summed over
dimensionless log-concentration space.

We also considered Loewe additivity (Loewe, 1928), the drug-with-
itself standard. At each combined concentration (X,Y), we used an
iterative approach (Berenbaum, 1985) to find the inhibition \( I_{Loewe} \) that
satisfies (X/X) + (Y/Y) = 1, where \( X \) and \( Y \) are the single agent
effect concentrations. Starting with a guess that \( I = I_{Loewe} \), we
interpolated the single agent curves to find \( X, Y \) that produce \( I \),
calculated the corresponding combination index, and used bisection
(Press et al, 1997) to converge on a value of \( I \) with combination index
\( C_1 = 1 \). Loewe additivity reduces to HSA at concentrations that are very
different from \( X, Y \), as well as for I above an agent’s limiting activity
(effectively \( X, Y \rightarrow \infty \)).

To model boosts in efficacy at high concentrations different from
what the single agents can achieve, we used a ‘Bliss boosting’ model,
adapting the Bliss independence model (Bliss, 1939) for boost levels
other than multiplicative. Mathematically, \( I_{max} = I_X + I_Y + \frac{1}{2}(I_X, I_Y) E_X E_Y \)
where \( E_X \) is the lesser of \( E_X \) and \( E_Y \), the limiting single agent
efficacies. The one free parameter \( b \), in units of effect, determines the
amount of boosting above \( E_{max} \), the greater of the single agent
efficacies. For inhibition effects, there are a number of useful reference
levels: \( \beta = -E_{max} \) produces ‘cancelling’, with zero effect at high
concentration; \( \beta = E_{min} - E_{max} \) is ‘suppression’, where the less
effective agent prevails; \( \beta = 0 \) yields ‘masking’, where the more
effective agent prevails; \( \beta = E_{max} - E_{min} \) is multiplicative (Bliss independence); and \( \beta = 1 \) produces ‘saturation’ at 100% inhibition. At the high
concentration limit, the suppressing, masking, multiplicative, and
saturating levels correspond to ‘suppression’, ‘buffering’, ‘no epista-
sis’, and ‘synthetic lethal’ in recent classifications for epistasis (Elena
and Lenski, 1997; Segré et al, 2005; Yeh et al, 2006). Bliss boosting can
be used in this form for any type of effect measure provided that the
single agent responses increase monotonically with concentration.
Only the saturating and multiplicative reference levels need to be
adjusted according to the measurement scale. For example, if we
consider fitness ratios (treated over untreated growth ratios) with
\( f = \ln(T/U) \) in place of inhibitions, there is no saturating level and
\( \beta = E_{max} \) indicates multiplicative. Note that Bliss masking is similar to
both HSA and Loewe additivity for very high or very low concentra-
tions where the single agent effects are almost flat.

Finally, we used a power-law ‘potentiation’ model to describe strong
shifts in potency similar to that seen for Bactrim® (Figure 1). For such
combinations, an active single agent’s response curve shows an
increase in potency as the enhancer is titrated in, which is seen as
linear iso-effect contours in serially diluted dose matrices (logarithmic
concentration space). The inhibition \( I_{potentiation} = \max(IX(C), IY) \)
where \( IX(C) \) is the single agent response curve of the potentiated compound,
was shifted at concentration \( C = X + (Y/Y_{pot}) |p| |sup| |p|, \) where \( |p| \) is a
unit sign function evaluated at \( (-1, 0, +1) \) corresponding to the sign
of its argument. Although the functional form presented here is

---

**Molecular Systems Biology** 2007
© 2007 EMBO and Nature Publishing Group
awkward, it was the simplest way we could find to achieve power-law potentiation and depotentiation above a threshold enhancer concentration, with the enhancer’s own activity superimposed. The two free parameters for this model are the threshold concentration $T_{pot}$ above which potentiation takes effect, and the potentiation slope $p$ (synergy for positive and antagonism for negative $p$). There is no potentiation for $p=0$, where this model reduces to an HSA surface. Just as for HSA and Loewe additivity, the form of this model is identical for any type of effect measure.

These models are not orthogonal; so we defined a fitting order to ensure an unambiguous choice. The shape models have degeneracies where two or more models can describe similar response shapes. Loewe additivity and HSA, for example, are largely degenerate, in that only when the single agents increase slowly over the sampled concentrations can a distinction between the two models be made. Nevertheless, both can be readily distinguished from Bliss boosting and potentiation, which themselves are distinct over a large range of their parameters, and many observed surfaces fit only one model effectively (Supplementary 2). To ensure an unambiguous choice that applies the principle of Occam’s razor when fitting several models to an observed surface, we ordered them by increasing complexity (HSA, Loewe, Bliss, potentiation) and declared as best fit the first model that was consistent with the observed surface. Without Bliss boosting, we classified combinations as cancelling, suppressing, masking, multiplicative, or saturating, depending on which fell closest to the best-fit $p$ for the observed response shape. Note that for some pairings, the boost levels cannot be separated. For example, if one single agent reaches 100% inhibition at high concentration, it will be impossible to distinguish saturating from multiplicative or masking levels. If both single agents reach 100%, only cancelling effects will be distinguishable from the others. For such boost level degeneracies, the first consistent level in the sequence above was chosen.

We note that these models were used primarily to characterize response surface shapes. Indeed, of the four shape models discussed here, only Loewe additivity has an a priori physical foundation as a predictive combination model. Although the original Bliss independence model (corresponding to the multiplicative level of Bliss boosting) is based on statistical independence, that foundation has no clear relevance to biological systems, where widely separated targets are neither statistically independent nor cleanly competing for the same end point. The Bliss boosting and potentiation models were included in our analysis to describe distinct shapes observed in our screens, and for well-sampled dose matrices neither is very good at fitting the effects that the other was designed to describe.

**Pathway simulations**

Simulations of metabolic pathways were performed using the XPPAUT ordinary differential equation simulation software (Ermentrout, 2002), on Boston University’s Biowulf computing cluster. The network shown in Figure 3 was modelled as a system of Michaelis–Menten enzymatic reactions, each with three kinetic parameters: the limiting reaction rate $V_{max}$, the rate constant $K_m$, and an exponential degradation rate $D_e$. The two pathways were driven by supplying substrates $S1$ and $S11$ from limitless sources with constant reaction velocities, and converting them through the enzymatic reactions before passing through the end-point reaction $R_2$ into a limitless sink. For symmetry and simplicity, we set all $V_{max}=1$ and $K_m=1$, and the degradations $D_e$ to a lower level of 0.01 in most cases. We used $D_e=1$ for substrates at bifurcations and for the final product of Pathway A to ensure illustrative differences in the single agent inhibitions (reducing response shape degeneracies) and to balance the flux through both pathways (for stable simulations). The system was initially started with all substrate levels set to 0.1 and run to steady state using an RK4 integration algorithm calculated at time intervals of 0.001 over 1000000 iterations, and the resulting substrate levels and parameter settings are shown in Supplementary 1. The combination response for each pair of inhibitors was determined using 100 simulations over a 10 x 10 dose matrix, where for each dosing point the targeted reactions were restricted by competitive inhibitors (that affect $K_m$) and the simulation was run for a further 600000 iterations using a step size of 0.005, before the inhibition $f=1-T/U$ was calculated on the treated end-point reaction velocity $T$, relative to the untreated velocity $U$. Optimal 9-point inhibitor concentration samples were chosen for each single agent by using a bisection search to find the single agent’s EC10 and EC90 concentrations, defining six samples with a fixed dilution factor $f=(EC90/EC10)^{1/2}$ to cover that range, and extending the total range with two additional concentration steps above the EC90 and one more below the EC10 at the same dilution factor $f$.

The resulting combination response data are tabulated in Supplementary 2. Each surface was compared to the models presented in Figure 2 (assuming 1% inhibition errors), and the best fit was determined to be HSA, Loewe additivity, Bliss boosting, or potentiation, in that order, depending on which was first consistent with the best-fitting model’s $\chi^2$ (where consistency meant that its $\chi^2$ was less than twice the best fit’s). Bliss boosting models were further classified as cancelling, suppressing, masking, multiplicative, or saturating, where it could be uniquely specified given the single agent limiting efficacies. The shape classifications, chi-squared, and best-fit parameter values are listed in Supplementary 2, and the shapes are also summarized in Figure 3. Supplementary Figure S1 compares the shape classifications and target connectivities from this simulation to epistasis calculations (Segré et al, 2005; Yeh et al, 2006) based on single concentration points taken from the matrices.

We varied the model parameters to explore the sensitivity of our results. First, we replaced the competitive inhibitor kinetics with non-competitive (affecting $V_{max}$) inhibition, performed the simulations, and repeated the model fitting to determine the best-fit response shapes. Second, we addressed the concern that a metabolic reaction velocity might provide a poor comparison to proliferation, the most accessible experimental end point. As proliferating cells undergo exponential doubling, a linear reduction of velocity by a factor $T/U$ for a growth-limiting metabolic reaction should slow the doubling time by a proportional factor. Over a time interval corresponding to $n$ uninhibited doublings, the resulting inhibition of cell population becomes $I_{growth} \approx 1-2^{-n}$, in terms of the velocity-based inhibition $I_v$. We applied this transformation to our simulated dose-matrix inhibitions for Pathway A, assuming $n=10$ doublings, and repeated the surface fitting procedure on the transformed dose matrices to determine the best-fit response shapes.

**Combination screening experiments**

The chemical library was archived in robotically accessible vials, to which diluent (dimethyl sulphoxide or water) was added in preparation for addition to 384-well master plates by a Tecan Freedom liquid-dispensing robot. Liquid transfers to dilution and assay plates were handled using a Perkin-Elmer MiniTrak station adapted for the combination high-throughput procedure. Each 384-well assay plate contained six $6 \times 6$ dose-matrix blocks, with four serial dilutions (two-fold for yeast and four-fold for HCT116) of the top concentration for each agent. Additional wells were reserved for transfer and untreated control wells. The compound mixtures were then added to the biological component of the assay as appropriate.

For the yeast experiment, C. glabrata (ATC #90030) cultures were cultured overnight in flasks with RPMI media in a 32°C shaker at 250 g.p.m. The next day the cultures were diluted so that they had an absorbance equivalent to 50% of McFarland standard, corresponding to a density of $\sim 8000$ cells/mL, and dispensed with automated dispensers into 384-well assay plates ($35 \mu$L wells containing media and test compounds) to yield $\sim 160$ cells/well. The plates were incubated in the presence of drugs and media at 32°C for 18 h
Upon completion, cell populations were measured at a single time point, with a metabolic Alamar Blue fluorescence reagent (at 590 nm emission) using a Perkin-Elmer Fusion plate reader after excitation at 535 nm.

For the tumour cell line experiment, the HCT116 (ATCC #CCL-247) cells were cultured in flasks with RPMI-1640 media for 2–20 passages, drawing test populations along the way. Extracts were trypsinized, counted, and seeded into 384-well plates at a density of 1500 cells/well in 35 μl media using automated dispensers. To ensure adherence, the plated cells were incubated at 37°C, with 5% CO₂ overnight, after which the compounds were added and the plates were incubated again at 37°C with 5% CO₂ for 72h (or about 2–3 doublings). After incubation, 10.5% Alamar Blue fluorescence dye (in 40μl media) was added and plates were incubated for 6h. Cell population measurements were made at a single time point upon completion, using a Perkin-Elmer Victor II plate reader (excitation at 535/590 nm emission).

This experimental procedure has a variety of sources for error in final proliferation measurements. Each compound is dissolved once in a single stock tube, and delivered into X- and Y-diluted master plates. Aliquots are then transferred from the master plates to each assay plate to produce the combinations. While this approach permits orthogonal serial dilutions and aids uniformity across instances of each compound, there can be systematic errors in compound plating between the X and Y masters for less stable compounds. Cells are seeded in media at high densities, to reduce the well-to-well variability, but occasional clogs in a pipette can lead to non-uniform distribution. During incubation, slight variations in temperature or humidity can lead to varying growth rates across wells on a plate and between plates.

Because the single cell population measurement is made during the exponential growth phase, variations can be amplified in the final readout, and this variation can be exaggerated when cells are sensitized by test compounds. The result of these various factors is that cell population measurements vary by ~1–3% on each plate, across untreated wells, and the variations do not fit a normal distribution. Moreover, some 1–2% of wells on each plate show occasional spikes that are very different from their neighbours.

The contents of each plate were tracked in an automated laboratory information management system, using integrated barcode scanners in the liquid handling equipment, and stored in an Oracle database. Plates lacking compound transfers or with insufficient dynamic range (signal-to-noise ratio <5 between untreated controls and a cell-free background) were rejected and repeated. The remaining plates were inspected using custom quality control software. Individual wells that fell outside the expected range for normal assay readouts, or which were discontinuous with their neighbours, were marked for exclusion.

Finally, the single agent wells in each combination block were visually inspected using custom quality control software. Individual wells that did not fit a normal distribution. Moreover, some 1–2% of wells on each plate show occasional spikes that are very different from their neighbours.

The contents of each plate were tracked in an automated laboratory information management system, using integrated barcode scanners in the liquid handling equipment, and stored in an Oracle database. Plates lacking compound transfers or with insufficient dynamic range (signal-to-noise ratio <5 between untreated controls and a cell-free background) were rejected and repeated. The remaining plates were inspected using custom quality control software. Individual wells that fell outside the expected range for normal assay readouts, or which were discontinuous with their neighbours, were marked for exclusion.

Each dose matrix was scored for synergy, and combination effects were compared to our response morphology models (Figure 2). Sigmoidal dose responses \(I = EC50/(S + C)\) as a function of concentration \(C\) were fitted to the single agent data, where \(E\) is the limiting efficacy at high concentration, \(S\) is the effective concentration, and \(a\) is the sigmoidicity or steepness of transition. These fitted curves were used for combination effect models. The HSA, Bliss boosting, and potentiation models were calculated, and the Loewe additivity model was solved at each dosing point by iterative root finding (Berenbaum, 1985). As a quantitative estimate of the combination activity, we computed HSA volume excess scores \(V_{HSA} = \Sigma X \ln f_X / f_X (\Sigma \text{drug}-\text{HSA})\), summed over all \(X \leq Y\), along with an associated error estimate \(\sigma_{V_{HSA}} = \sqrt{\Sigma X X \ln^2 f_X \ln f_Y (\Sigma \text{data})}\), both expressions using adjustments to account for differing dilution factors \(f_X, f_Y\). This volume measures the total excess inhibition, summed over dimensionless log-concentration space. Data surfaces were compared to the shapes presented in Figure 2 by varying the model parameters, using a Nelder-Mead simplex algorithm (Press et al., 1997, §10.4) to minimize \(\chi^2 = \Sigma (\text{data} - \text{model}) / \Sigma (\text{data})\), the reduced chi-squared. All four models were explored, and the overall best fit with the least chi-square \(\chi^2_{\text{data}}\) was chosen to represent the shape of the combination. A best fit was chosen from HSA, additivity, boosting, or potentiation, in that order, depending on which was first consistent with the \(X_{\text{min}}\).

Finally, systematic errors that were not captured by our error estimates from replicates can be estimated by examining the drug-with-self combinations as a negative control for combination effect. For both screens, the median Loewe additivity \(\chi^2\) was ~9, suggesting that the true reproducibility of drug response was roughly three times the estimated levels from the scatter between replicates. This suggests systematic errors of ~10% at each dose-matrix point, leading to integrated volume error estimates of \(\sigma_{\text{HSA}} \sim 0.4\). Thus, only combination effects with \(V_{\text{HSA}} > 1\) are strong enough to be reliably distinguishable from drug-with-itself combinations.

For the HCT116 combination screen, synergy profiles were constructed for each drug by collecting into a vector all the \(V_{\text{HSA}}\) scores involving that chemical. These profiles were then compared for all pairs of drugs in the screen by means of the Pearson correlation coefficient. The synergy profile correlations and synergy scores were grouped by the target similarity (Supplementary 5) of the two drugs in each combination, and classified as follows: ‘Identical’ for drug-with-itself; ‘Same’ for distinct drugs inhibiting the same target; ‘Related’ for differing targets sharing a common functional group; ‘Kinases’ for combinations of kinase inhibitors; ‘Different’ for unrelated pairs of drugs; and ‘Unknown’ for pairs involving one or more unknown mechanism. The target similarity group distributions were compared for significant differences using a chi-square test that assumes only Poisson counting statistics within each bin in the histograms (Press et al., 1997, §14.3.3).

Supplementary information

Supplementary information is available at the Molecular Systems Biology website (www.nature.com/msb).

Acknowledgements

This work was enabled and assisted by many people at CombinatoRx. We are grateful to Boston University’s Department of Bioengineering for providing access to the Biowulf computing cluster, and to Tim Gardner for co-advising Andrew Krueger’s thesis. Herbert Sauro, Baltz Aguda, Mike Foley, Trey Ideker, and Leroy Hood gave encouragement and advice at key points. We also thank the referees for very helpful comments. Brent Stockwell is supported in part by a Career Award at the Scientific Interface from the Burroughs Wellcome Fund.

Competing financial interests statement

The authors declare competing financial interests.
References

Ashford JR, Cobby JM (1974) A system of models for the action of drugs applied singly or jointly to biological organisms. *Biometrics* **30**: 11–31

Awwad RA, Sergina N, Yang H, Ziobet B, Willson JK, Zbrowowska E, Humphrey LE, Fan R, Ko TC, Brattain MG, Howell GM (2003) The role of transforming growth factor alpha in determining growth factor independence. *Cancer Res* **63**: 4731–4738

Berenbaum MC (1985) The expected effect of a combination of agents: the general solution. *J Theor Biol* **114**: 413–431

Berenbaum MC (1989) What is synergy? *Pharmacol Rev* **41**: 93–141

Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G (2000) Apldronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. *Arch Biochem Biophys* **373**: 231–241

Bliss CI (1939) The toxicity of poisons applied jointly. *Ann Appl Biol* **26**: 585–615

Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehár J, Price ER, Serbedzija G, Folev MA, Stockwell BR, Keith CT (2003) Systematic discovery of multi-target components. *Proc Natl Acad Sci USA* **100**: 7977–7982

Bouwmeester T, Bauch A, Ruffner H, Angrand PO, Bergamini G, Ann Appl Biol **128**: 93–100

Bouwmeester T, Bauch A, Ruffner H, Angrand PO, Bergamini G, Famili I, Forster J, Nielsen J, Palsson BO (2003) *Saccharomyces cerevisiae* genome-scale reconstruction of metabolic network. *Mol Systems Biol* **2007** EMBO and Nature Publishing Group Molecular Systems Biology 2007 295: 1669–1678

Baptist, M. D., Lawton G, Nixon JS, Wilkinson SE (1992) Inhibitors of protein kinase C. *Nat Cell Biol* **6**: 97–105

Carter Jr WH, Wampler GL (1986) Review of the application of response surface methodology in the combination therapy of cancer. *Cancer Treat Rep* **70**: 133–140

Chou TC, Talalay P (1983) Analysis of combined drug effects: a new look at a very old problem. *Trends Pharmacol Sci* **4**: 450–454

Csermely P, Agoston V, Ghidelli S, Hofp C, Huhse B, Mangano R, Michon AM, Schirle M, Schlegl J, Schwab M, Stein MA, Bauer A, Casari G, Drewes G, Gavin AC, Jackson DB, Jofferty G, Neubauer G, Rick J, Ruster B, Superti-Furga G (2004) A physical and functional map of the human ini-alpha/ini-kappa b signal transduction pathway. *Nat Cell Biol* **6**: 97–105

Carter Jr WH, Wampler GL (1986) Review of the application of response surface methodology in the combination therapy of cancer. *Cancer Treat Rep* **70**: 133–140

Chou TC, Talalay P (1983) Analysis of combined drug effects: a new look at a very old problem. *Trends Pharmacol Sci* **4**: 450–454

Csermely P, Agoston V, Gongor S (2004) The efficiency of multi-target drugs: the network approach might help drug design. *arXiv* 1669–1678

Davidson EH, Rast JP, Bittner MA, Spellman PT, Alizadeh AA, friesen, C. E., Botstein D, Botvinnik OI, Brown PO, Clapper AL, Darnell JR, et al. (2002) A genomic regulatory network for development. *Science* **295**: 114–120

Deo RC, Stockwell BR, Keith CT (2005) Multicomponent drug design: the network approach might help drug design. *Chem Tal 2004* **13**: 413–431

Favata MF, Horiuichi KY, Manos EJ, Daulerio AJ, Stradley DA, Feerer WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherer PA, Trzaskos JM (1998) Identification of a novel inhibitor of mitogenic-activated protein kinase kinase. *J Biol Chem* **273**: 18623–18632

Filliben JJ (2005) Exploratory data analysis. *Engineering Statistics Handbook, Internet, National Institute of Standards and Technology* http://www.itl.nist.gov/div898/handbook/eda/ section3/eda365.htm

Fojo T, Bates S (2003) Strategies for reversing drug resistance. *Oncogene* **22**: 7512–7523

Fox T, Coll JT, Xie X, Ford PJ, Germann UA, Porter MD, Pazhanisamy S, Fleming MA, Galullo V, Su MSS, Wilson KP (1998) A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase. *Protein Sci* **7**: 2249–2255

Gardner RG, Shan H, Matsuda SP, Hampton RY (2001) An oxysterol-derived positive signal for 3-hydroxy-3-methylglutaryl-CoA reductase degradation in yeast. *J Biol Chem* **276**: 8681–8694

Giaever G, Flaherty P, Kumm J, Proctor M, Nislow C, Jaramillo DF, Chu AM, Jordan MI, Arkin AP, Davis RW (2004) Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. *Proc Natl Acad Sci USA* **101**: 793–798

Greco WR, Bravo G, Parsons JC (1995) The search for synergy: a critical review from a response surface perspective. *Pharmacol Rev* **47**: 331–385

Gschwendt M, Muller HJ, Kielbassa K, Zang R, Kinttstein W, Rincke G, Marks F (1994) Rottlerin, a novel protein kinase inhibitor. *Biochem Biophys Res Commun* **199**: 93–98

Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R (1999) Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. *Nat Biotechnol* **17**: 994–999

Hagarty SJ, Clemons PA, Schreiber SL (2003) Chemical genomic profiling of biological networks using graph theory and combinations of small molecule perturbations. *J Am Chem Soc* **125**: 10543–10545

Harrap KR, Jackson RC (1975) Enzyme kinetics and combination chemotherapy: an appraisal of current concepts. *Adv Enzyme Regul* **13**: 77–96

Hartman IV JL, Tipperly NP (2004) Systematic quantification of gene interactions by phenotypic array analysis. *Genome Biol* **5**: R49

Ho V, Gruhler A, Heilbut A, Bader GD, Moore L, Adams SL, Millar A, Taylor P, Bennett K, Boutillier K, Lang W, Wolting C, Donaldson I, Schandorff S, Shewnarane J, Vo M, Taggart J, Goudreau M, Muskat B, Afarano C, Dewar D, Lin Z, Michalikova K, Willems AR, Sassi H, Nielsen PA, Rasmussen KI, Andersen J, Johansen LE, Hansen LH, Jespersen H, Podtelejnikov A, Nielsen E, Crawford J, Poulsen V, Sorensen BD, Matthiesen J, Hendrickson RC, Gleeson F, Pawson T, Moran MF, Durocher D, Mann M, Hogue CW, Figeys D, Tyers M (2002) Systematic identification of protein complexes in *Saccharomyces cerevisiae* by mass spectrometry. *Nature* **415**: 180–183

Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, Armour CD, Bennett HA, Coffey E, Dai H, He YD, Kidd MJ, King AM, Meyer MR, Slade D, Lum PY, Stepaniants SB, Shoemaker DD, Chagotse D, Chakraborty K, Simon J, Bard M, Friend SH (2000) Functional discovery via a compendium of expression profiles. *Cell* **102**: 109–126

Ideker T, Galitski T, Hood L (2001) A new approach to decoding life: systems biology. *Annu Rev Genomics Hum Genet* **2**: 433–372

Jackson RC (1993) Amphibolic drug combinations: the design of selective antimetabolite protocols based upon the kinetic properties of multienzyme systems. *Cancer Res* **53**: 3998–4003

Keith CT, Borisy AA, Stockwell BR (2005) Multicomponent therapeutics for networked systems. *Nat Rev Drug Discov* **4**: 1–8

Kishony R, Leibler S (2003) Environmental stresses can alleviate the average deleterious effect of mutations. *J Biol* **2**: 14

Komarova NL, Wodarz D (2005) Drug resistance in cancer: principles of emergence and prevention. *Proc Natl Acad Sci USA* **102**: 9714–9719

Lee TI, Rinaldi NJ, Robert F, Odom DT, Bar-Joseph Z, Gerber GK, Hannett NM, Harbison CT, Thompson CM, Simon I, Zeitlinger J, Jennings EG, Murray HL, Gordon DB, Ren B, Wyrick JJ, Tagne JB, Volkert TL, Fraenkel E, Gifford DK, Young RA (2002) Transcriptional regulatory networks in *Saccharomyces cerevisiae*. *Science* **298**: 799–804
Chemical combinations and target connectivity

J Lehäuser et al

Loewe S (1928) Die quantitativen probleme der pharmakologie. *Ergeb Physiol* 27: 47–187

Lorenz RT, Parks LW (1990) Effects of lovastatin (mevinolin) on sterol levels and on activity of azoles in *Saccharomyces cerevisiae*. *Antimicrob Agents Chemother* 34: 1660–1665

Lum PY, Armour CD, Stepaniants SB, Cavet G, Wolf MK, Butler JS, Hinshaw JC, Garnier P, Prestwich GD, Leonardson A, Garrett-Engele P, Rush CM, Bard M, Schimmack G, Phillips JW, Roberts CJ, Shoemaker DD (2004) Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heteroygotes. *Cell* 116: 121–137

MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK (2006) Identifying off-target effects and hidden phenotypes of drugs in human cells. *Nat Chem Bio* 2: 329–337

Milo R, Shen-Orr S, Itzkovitz S, Kashtan N, Chklovskii D, Alon U (2002) Network motifs: simple building blocks of complex networks. *Science* 298: 824–827

Okada T, Sakuma L, Fukui Y, Hazeki O, Ui M (1994) Blockage of chemotactic peptide-induced stimulation of neutrophils by wortmannin as a result of selective inhibition of phosphatidylinositol 3-kinase. *J Biol Chem* 269: 3563–3567

Ozier O, Amin N, Ideker T (2003) Global architecture of genetic interactions on the protein network. *Nat Biotechnol* 21: 490–491

Parsons AB, Brost RL, Ding H, Li Z, Zhang C, Sheikh B, Brown GW, Kane PM, Hughes TR, Boone C (2004) Integration of chemical-geometric and genetic interaction data links bioactive compounds to cellular target pathways. *Nat Biotechnol* 22: 62–69

Perlman ZE, Slack MD, Feng Y, Mitchison TJ, Wu LF, Altschuler SJ (2004) Multidimensional drug profiling by automated microscopy. *Science* 306: 1194–1198

Press WH, Teukolsky SA, Vetterling WT, Flannery BP (1997) *Recipes in c: The Art of Scientific Computing*. 2nd edn. Cambridge: CUP

Rine J, Hansen W, Hardeman E, Davis RW (1983) Targeted selection of recombinant clones through gene dosage effects. *Proc Natl Acad Sci USA* 80: 6750–6754

Schlessinger J (2004) Common and distinct elements in cellular signaling via EGF and FGF receptors. *Science* 306: 1506–1507

Schoenholz B, Eichler-Jonsson C, Gilles ED, Muller G (2002) Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. *Nat Biotechnol* 20: 370–375

Segrè D, Deluna A, Church GM, Kishony R (2005) Modular epistasis in yeast metabolism. *Nat Genet* 37: 77–83

Shirasawa S, Furuse M, Yokoyama N, Sasazuki T (1993) Altered growth of human colon cancer cell lines disrupted at activated ki-ras. *Science* 260: 85–88

Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, Tyers M (2006) Biogrid: a general repository for interaction datasets. *Nucleic Acids Res* 34 (Database issue): D535–D539

Terrell CL, Hughes CE (1992) Antifungal agents used for deep-seated mycotic infections. *Mayo Clin Proc* 67: 69–91

Wills EA, Redinbo MR, Perfect JR, Del Poeta M (eds) (2000) *New Potential Targets for Antifungal Development*. Expert opinion on therapeutic targets. London: Ashley

Yano H, Agatsuama T, Nakanishi S, Saitoh Y, Fukui Y, Nonomura Y, Matsuda Y (1995) Biochemical and pharmacological studies with KT7692 and LY294002 on the role of phosphatidylinositol 3-kinase in Fc epsilon RI-mediated signal transduction. *Biochem J* 312: 145–150

Yeh P, Tschumi AI, Kishony R (2006) Functional classification of drugs by properties of their pairwise interactions. *Nat Genet* 38: 489–494

Zimmermann GR, Lehäuser J, Keith CT (2007) Multi-target-therapeutics: when the whole is greater than the sum of the parts. *Drug Discov Today* 12: 34–42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17198971